Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Discover a new trial that has evaluated and personalised treatments for metastatic castration-resistant prostate cancer, ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Throughout any given year, the National Academies convene hundreds of conferences, workshops, symposia, forums, roundtables, and other gatherings that attract the finest minds in academia and the ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary ...

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

The median age was 72 years in both arms (overall range, 45-92 years). Most patients had metastases at the start of prior ARPI therapy, and a minority had received prior taxane treatment. The median ...

ROCKVILLE, MD, USA I 15, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...